🚀 VC round data is live in beta, check it out!
Kalbe Farma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kalbe Farma and similar public comparables like Organon, United Laboratories International, ADMA Biologics, Mineralys Therapeutics and more.
Kalbe Farma Overview
About Kalbe Farma
PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
Founded
1966
HQ
Employees
16.7K
Website
Financials (LTM)
EV
$2B
Kalbe Farma Financials
Kalbe Farma reported last 12-month revenue of $2B and EBITDA of $316M.
In the same LTM period, Kalbe Farma generated $841M in gross profit, $316M in EBITDA, and $216M in net income.
Revenue (LTM)
Kalbe Farma P&L
In the most recent fiscal year, Kalbe Farma reported revenue of $2B and EBITDA of $312M.
Kalbe Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $841M | XXX | $822M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $316M | XXX | $312M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $216M | XXX | $214M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kalbe Farma Stock Performance
Kalbe Farma has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Kalbe Farma's stock price is $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKalbe Farma Valuation Multiples
Kalbe Farma trades at 1.1x EV/Revenue multiple, and 7.3x EV/EBITDA.
EV / Revenue (LTM)
Kalbe Farma Financial Valuation Multiples
As of April 19, 2026, Kalbe Farma has market cap of $3B and EV of $2B.
Equity research analysts estimate Kalbe Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kalbe Farma has a P/E ratio of 11.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBIT | 8.4x | XXX | 8.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | 2.8x | XXX | XXX | XXX |
| P/E | 11.7x | XXX | 11.8x | XXX | XXX | XXX |
| EV/FCF | 18.3x | XXX | 15.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kalbe Farma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kalbe Farma Margins & Growth Rates
Kalbe Farma's revenue in the last 12 month grew by 7%.
Kalbe Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Kalbe Farma's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kalbe Farma's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kalbe Farma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kalbe Farma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kalbe Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Organon | XXX | XXX | XXX | XXX | XXX | XXX |
| United Laboratories International | XXX | XXX | XXX | XXX | XXX | XXX |
| ADMA Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mineralys Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kalbe Farma M&A Activity
Kalbe Farma acquired XXX companies to date.
Last acquisition by Kalbe Farma was on XXXXXXXX, XXXXX. Kalbe Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kalbe Farma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKalbe Farma Investment Activity
Kalbe Farma invested in XXX companies to date.
Kalbe Farma made its latest investment on XXXXXXXX, XXXXX. Kalbe Farma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kalbe Farma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kalbe Farma
| When was Kalbe Farma founded? | Kalbe Farma was founded in 1966. |
| Where is Kalbe Farma headquartered? | Kalbe Farma is headquartered in Indonesia. |
| How many employees does Kalbe Farma have? | As of today, Kalbe Farma has over 16K employees. |
| Is Kalbe Farma publicly listed? | Yes, Kalbe Farma is a public company listed on Indonesia Stock Exchange. |
| What is the stock symbol of Kalbe Farma? | Kalbe Farma trades under KLBF ticker. |
| When did Kalbe Farma go public? | Kalbe Farma went public in 1991. |
| Who are competitors of Kalbe Farma? | Kalbe Farma main competitors are Organon, United Laboratories International, ADMA Biologics, Mineralys Therapeutics. |
| What is the current market cap of Kalbe Farma? | Kalbe Farma's current market cap is $3B. |
| What is the current revenue of Kalbe Farma? | Kalbe Farma's last 12 months revenue is $2B. |
| What is the current revenue growth of Kalbe Farma? | Kalbe Farma revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Kalbe Farma? | Current revenue multiple of Kalbe Farma is 1.1x. |
| Is Kalbe Farma profitable? | Yes, Kalbe Farma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kalbe Farma? | Kalbe Farma's last 12 months EBITDA is $316M. |
| What is Kalbe Farma's EBITDA margin? | Kalbe Farma's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Kalbe Farma? | Current EBITDA multiple of Kalbe Farma is 7.3x. |
| What is the current FCF of Kalbe Farma? | Kalbe Farma's last 12 months FCF is $125M. |
| What is Kalbe Farma's FCF margin? | Kalbe Farma's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Kalbe Farma? | Current FCF multiple of Kalbe Farma is 18.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.